NEW YORK--(BUSINESS WIRE)--Petrichor Healthcare Capital Management (“Petrichor”), a healthcare investment firm, today announced the appointment of Peter Greenleaf to its Advisory Board.
Currently Chief Executive Officer and a board member of Cerecor, Inc., a pediatric commercial organization and leading developer of orphan neurological therapies, and Chairman of the Board of BioDelivery Sciences, a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine, Mr. Greenleaf brings to Petrichor over two decades of biopharmaceutical experience. Previously, Mr. Greenleaf served as Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc., a company focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide. Under Mr. Greenleaf’s direction, Sucampo was sold to Mallinckrodt Pharmaceuticals in February 2018 for $1.2 billion.
Prior to this, Mr. Greenleaf established himself as a key strategic operator within organizations including Histogenics Corporation, a preeminent regenerative medicine company, where he served as Chief Executive Officer and a member of the board of directors; MedImmune, the global biologics arm of AstraZeneca, where he served as President; MedImmune Ventures, where he led the activities of AstraZeneca’s wholly-owned venture capital fund; Centocor Biotech, Inc., now Janssen Biotech, owned by Johnson & Johnson; and Boehringer Mannheim G.m.b.H, now Roche Holdings, where he held senior commercial and corporate development roles. Additionally, Mr. Greenleaf has a wide array of private and public company board experience and actively chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. He is also a former board member of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Industry Organization (BIO), where he served on the Governing Boards of the Emerging Companies and Health Sections.
“I have worked closely with members of the Petrichor team and have seen first-hand the strategic value they provide to companies in both transactional and operational settings,” Mr. Greenleaf said. “I believe the Petrichor platform is poised for tremendous success, and I look forward to supporting the team as they partner with world-class healthcare executives.”
Petrichor Founder and Managing Partner Tadd S. Wessel welcomed Mr. Greenleaf to the team, saying, “We are honored to have Peter join Petrichor’s Advisory Board. He has built several successful biopharmaceutical companies, and demonstrated an incredible ability to create value through organic growth as well as M&A. Peter’s acumen spans drug development, commercialization, investing, and industry policy. We are thrilled by the experience he brings to our platform.”
Mr. Greenleaf joins Sir Bruce Keogh, Former National Medical Director for NHS England, on Petrichor’s Advisory Board. The Board assists Petrichor’s investment team in their identification, diligence, and support of investment opportunities, including serving on the board of directors of portfolio companies.
About Petrichor Healthcare Capital Management
Petrichor Healthcare Capital Management partners with world-class healthcare managers and businesses to provide customized investment structures and support. The Petrichor team of investment professionals comes from best-in-class financial institutions including OrbiMed and Fortress Investment Group. Collectively, the team has completed over 75 investments representing more than $5 billion in invested capital and has held over 25 board seats. Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise. This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a strong competitive advantage.